Ad5-D24-GMCSF
AXP000066.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, Delta-24, GM-CSF-armed)
- Originator
- University of Helsinki (Akseli Hemminki)
Names
| Name | Type | Source |
|---|---|---|
| Ad5-D24-GMCSF | preferred name, code | curator, paper |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- conditionally replicating
- Modifications
- 24-bp E1A CR2 deletion (Delta-24)
- Transgenes
- CSF2
- Route
- intratumoral, intraperitoneal, intrapleural, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 20484030 | Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. | Cancer research | 2010 | name in abstract: Ad5-D24-GMCSF |
Notes
Given to patients in the Finnish Advanced Therapy Access Program (ATAP, 2007-2012), an individualised-treatment programme rather than a registered trial. Serotype 5 fibre version of the virus that became ONCOS-102 (Ad5/3).
How to cite
Ad5-D24-GMCSF (AXP000066.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000066.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.